CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.
Smart weather app helps Kenya s herders brace for drought
Tuesday, 16 February 2021 12:52 GMT
A young man at Merille Livestock Market in northern Kenya receives a call to alert him of the week’s weather forecast transmitted through the myAnga app, Merille, Kenya, on Feb. 2, 2021. Thomson Reuters Foundation/Kagondu Njagi
About our Climate coverage We focus on the human and development impacts of climate change
Share: App gets forecasts from virtual weather stations Information can save herders scouting as far as 120 km Illiteracy and low smartphone access limit app s reach
By Kagondu Njagi
MERILLE, Kenya, Feb 16 (Thomson Reuters Foundation) - Sitting under a low tree to escape the blazing Kenyan sun, Kaltuma Milkalkona and two young men hunch intently over the older woman s smartphone - but they are not transfixed by the latest sports scores or a trending internet meme.
The Coalition for Epidemic Preparedness Innovations (CEPI) has set out a $3.5bn plan to ‘dramatically reduce or even eliminate the future risk of pandemics’. Its ambitions are for an ‘all-in-one’ vaccine against SARS, MERS-CoV and SARS-CoV-2 coronaviruses; as well as reducing vaccine development into a 100 day timeframe.
(2)
Up to $33m of funding will support development of VBI s enveloped virus-like particle (eVLP) vaccine candidates against COVID-19 variants of concern.
Phase 1 clinical study of VBI s eVLP vaccine candidate, VBI-2905, targeting the B.1.351 variant, anticipated to initiate mid-year 2021.
CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. (Nasdaq: VBIV), today announced a partnership to develop VBI s enveloped virus like particle (eVLP) vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant, also known as 501Y.V2, first identified in South Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005316/en/
CEPI will provide up to $33m to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the B.1.351 strain, through Phase 1 clinical development. As part of the agreement, this funding will als
COVID-19 vaccines shipped by COVAX arrive in Sierra Leone
Format
Freetown, Sierra Leone, Monday 8 March 2021 - Today, Sierra Leone received the first batch of 96,000 doses of the AstraZeneca-Oxford COVID-19 vaccine shipped via the COVAX Facility, a partnership between the Government Sierra Leone, CEPI, Gavi, UNICEF and WHO. This is a historic step towards our goal to ensure equitable distribution of COVID-19 vaccines globally, in what will be the largest vaccine procurement and supply operation in history. The delivery is part of a first wave of arrivals of an initial 528,000 doses that will continue till end of May 2021.
On 6 March 2021, COVAX shipped 96,000 doses of the AstraZeneca vaccine, licensed and manufactured by Serum Institute (PVT) Limited from Maharashtra, India, to Freetown, Sierra Leone, arriving in the evening of 8 March 2021. The arrival of this first batch of 528,000 doses will kick start the vaccination of 20% of Sierra Leone’s 8,000,000 population as part of t